EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

The Lancet Oncology - Tập 13 - Trang 33-42 - 2012
Robert Pirker1, Jose R Pereira2, Joachim von Pawel3, Maciej Krzakowski4, Rodryg Ramlau5, Keunchil Park6, Filippo de Marinis7, Wilfried EE Eberhardt8, Luis Paz-Ares9, Stephan Störkel10, Karl-Maria Schumacher11, Anja von Heydebreck11, Ilhan Celik11, Kenneth J O'Byrne12
1Department of Medicine I, Medical University Vienna, Vienna, Austria
2Arnaldo Vieira de Carvalho Cancer Institute, Onco-Pneumology, São Paulo, Brazil
3Asklepios Fachkliniken, München-Gauting, Germany
4Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland
5Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznan University of Medical Sciences, Poznan, Poland
6Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, South Korea
71st Oncological Pulmonary Unit, San Camillo-Forlanini Hospital, Rome, Italy
8Department of Medicine (Cancer Research), West German Tumor Centre, University of Duisburg-Essen, Essen, Germany
9Instituto de Biomedicina de Sevilla and Hospital Universitario Virgen del Rocio, Seville, Spain
10HELIOS Hospital Wuppertal, University Witten/Herdecke, Wuppertal, Germany
11Merck KGaA, Darmstadt, Germany
12St James's Hospital, Dublin, Ireland

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Oncology

Tập 13

33-42

Thông tin tác giả